Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study

Hu Mao Gui, Jing Ming, Jing Wang, Guolin Wu, Dandan Fan, Yuanyuan Feng, Xinchen Wang, Linlin Cao, Hao Song, CuiCui Wang, Qiang Xu, ChenYang Zhou, Kaiyang Ding

Blood (2025) 146 (Supplement 1): 3597.

https://doi.org/10.1182/blood-2025-3597

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study

Zhiming Li, Peng SUN, Kaiyang Ding, Gang Huang, Hang Yang, Yu Wang

Blood (2025) 146 (Supplement 1): 3639.

https://doi.org/10.1182/blood-2025-3639

Published: 2025

Journal Articles

Orelabrutinib combined with short-course bendamustine-rituximab (BR) for first-line treatment of chronic lymphocytic leukemia: A prospective multicenter study

Linlin Cao, Hao Song, Guolin Wu, Hu Mao Gui, Qiang Xu, CuiCui Wang, Dandan Fan, Yuanyuan Feng, ChenYang Zhou, Jing Ming, Xinchen Wang, Jing Wang, Meiqi Ding, Youzhi Wu, Long Zhong, Kaiyang Ding

Blood (2025) 146 (Supplement 1): 2127.

https://doi.org/10.1182/blood-2025-2127

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL)

Blood (2025) 146 (Supplement 1): 266.

https://doi.org/10.1182/blood-2025-266

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2025-5666

Published: 2025

Journal Articles

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Haiyan Yang, Kaiyang Ding, Cong Li, Weihao Zhuang, Yangjie Ru, Jieyu Xu, Xinchen Wang, XI Chen, Xiaowu Dong, Tao Lei, Jialiang Lu

Blood (2025) 146 (Supplement 1): 5305.

https://doi.org/10.1182/blood-2025-5305

Published: 2025

Journal Articles

Data update of a single-arm, Phase II Study of orelabrutinib with/without Rituximab in patients with chronic lymphocytic leukemia/small Lymphocytic Lymphoma after BTK inhibitor therapy

Blood (2025) 146 (Supplement 1): 7416.

https://doi.org/10.1182/blood-2025-7416

Published: 2025

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study

Orelabrutinib combined with short-course bendamustine-rituximab (BR) for first-line treatment of chronic lymphocytic leukemia: A prospective multicenter study

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL)

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Data update of a single-arm, Phase II Study of orelabrutinib with/without Rituximab in patients with chronic lymphocytic leukemia/small Lymphocytic Lymphoma after BTK inhibitor therapy

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only